These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19791315)

  • 41. 2011-2012 National health law moot court competition: introduction & problem.
    Spielman BJ
    J Leg Med; 2012 Oct; 33(4):429-57. PubMed ID: 23216147
    [No Abstract]   [Full Text] [Related]  

  • 42. Product liability and prescription diet drug cocktail, Fen-Phen: a hard combination to swallow.
    Crisanti CA
    J Contemp Health Law Policy; 1998; 15(1):207-44. PubMed ID: 9988998
    [No Abstract]   [Full Text] [Related]  

  • 43. Court rules generic drug companies not responsible for adverse outcomes.
    Kouros N
    Monash Bioeth Rev; 2013 Sep; 31(2):23-4. PubMed ID: 24844072
    [No Abstract]   [Full Text] [Related]  

  • 44. Warning label limbo. FDA rule letting generic-drug makers update risk alerts draws heavy flak.
    Carlson J
    Mod Healthc; 2014 Jun; 44(26):20-2. PubMed ID: 25134408
    [No Abstract]   [Full Text] [Related]  

  • 45. Digital gangrene induced by inadvertent intra-arterial cocktail injection of anesthetic agents such as pentazocine, promethazine, and atropine: A serious adverse drug experience.
    Mahajan SS; Tandon VR; Sarin R; Roshi ; Gupta AK; Kohli A
    Indian J Pharmacol; 2018; 50(6):354-357. PubMed ID: 30783330
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Law's knowledge: science for justice in legal settings.
    Jasanoff S
    Am J Public Health; 2005; 95 Suppl 1():S49-58. PubMed ID: 16030338
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Off-label drug use and promotion: balancing public health goals and commercial speech.
    Kesselheim AS
    Am J Law Med; 2011; 37(2-3):225-57. PubMed ID: 21847880
    [No Abstract]   [Full Text] [Related]  

  • 48. AHI perspectives: flexible drug labeling and its impact on the drug development process. Liability issues.
    Thomas JW
    J Am Vet Med Assoc; 1995 Oct; 207(7):899-900; discussion 902-4. PubMed ID: 7559021
    [No Abstract]   [Full Text] [Related]  

  • 49. A strike against preemption.
    Nat Biotechnol; 2009 May; 27(5):397. PubMed ID: 19430422
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Highlights and a hidden hazard--the FDA's new labeling regulations.
    Avorn J; Shrank W
    N Engl J Med; 2006 Jun; 354(23):2409-11. PubMed ID: 16760439
    [No Abstract]   [Full Text] [Related]  

  • 51. The continuing search for proper perspective: whose reasonableness should be at issue in a prescription product design defect analysis?
    Cupp RL
    Spec Law Dig Health Care Law; 2000 Dec; (260):9-33. PubMed ID: 11149134
    [No Abstract]   [Full Text] [Related]  

  • 52. Manufacturers' liability for drugs and medical devices under the Restatement (Third) of Torts: Products Liability.
    Dreier WA
    Seton Hall Law Rev; 1999; 30(1):258-64. PubMed ID: 10848105
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tort claims and federal regulation of medical devices vs pharmaceuticals.
    Green M
    JAMA; 2009 Sep; 302(11):1169; author reply 1169-70. PubMed ID: 19755694
    [No Abstract]   [Full Text] [Related]  

  • 54. Pros and cons of off-label promotion investigations and prosecutions.
    Loucks MK
    Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
    [No Abstract]   [Full Text] [Related]  

  • 55. License to maim: federal pre-emption and the Medical Device Amendments of 1976.
    Petrella ME
    Health Matrix Clevel; 1996; 6(2):349-89. PubMed ID: 10178392
    [No Abstract]   [Full Text] [Related]  

  • 56. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
    Poser S
    Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225
    [No Abstract]   [Full Text] [Related]  

  • 57. FDA preemption of drug and device labeling: who should decide what goes on a drug label?
    Valoir T; Ghosh S
    Health Matrix Clevel; 2011; 21(2):555-98. PubMed ID: 22145525
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Riegel v. Medtronic, Inc.: revisiting pre-emption for medical devices.
    Patsner B
    J Law Med Ethics; 2009; 37(2):305-17. PubMed ID: 19493075
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Federal regulatory pre-emption of state tort claims against the manufacturers of medical devices and pharmaceutical drugs.
    Jacobstein JM
    J Law Med Ethics; 2008; 36(3):594-7. PubMed ID: 18840254
    [No Abstract]   [Full Text] [Related]  

  • 60. Products liability: Supreme Court denies federal preemption claims under MDA.
    Wilson SD
    J Law Med Ethics; 1997; 25(1):76-7. PubMed ID: 11066484
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.